TruDiagnostic

TruDiagnostic is a biodata research company that offers epigenetic age prediction tests. TruDiagnostic reportedly possesses the largest private epigenetic database in the world. It conducts DNA methylation-based research and discovery and develops methylation-based diagnostic tools.

The company claims to offer the most advanced epigenetic analysis currently available by examining over one million locations on DNA and using its technology to provide interpretations that give actionable feedback.

The company also offers third-party laboratory testing, including epigenomics, genomics, proteomics, and bioinformatics.

As of October 2023, TruDiagnostic reportedly had over 30,000 participating cash-pay medicine physicians and had access to more than 15,000 consenting patients who had provided a range of covariates and longitudinal testing data. In addition, the company claims to have had over 30 research trials underway, with collaborations from universities such as Harvard, Duke, Columbia, Berkeley, Stanford, etc. as of the same date.

Key customers and partnerships

The company partnered with Czech-Republic-based longevity-focused distributor HealthyLongevity.global in June 2022 to distribute its epigenetic biological age tests within Europe.

In February 2023, TruDiagnostic partnered with Rejuve.AI, an AI-powered longevity research network, to develop more accurate tools for predicting chronological ages. The collaboration seeked to further explore the biology of aging and connectedness of DNA methylation, metabolomics, and proteomics.

The company collaborated with NADMED, a developer of the metabolite extraction system, in March 2023 to launch NAD blood tests in the US. Through this collaboration, physicians were to obtain access to NAD blood diagnostic for their patients. The TruDiagnostic kit allows blood collection at doctors’ offices or at home. After posting the samples to the TruDiagnostic laboratory, they are analyzed with NADMED technology.